Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 12/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17816464 | 0.85 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C19ALDH1A1GAA | |
| SCHEMBL17816217 | 0.74 | KMT2A (0.43) | CYP3A4CYP2C19ALDH1A1GAAKDM4E | |
| SCHEMBL17808229 | 0.74 | GABRA1 (0.39) | ALDH1A1GAAHPGDL3MBTL1AR | |
| SCHEMBL17808225 | 0.74 | GABRA1 (0.39) | ALDH1A1GAAHPGDL3MBTL1AR | |
| SCHEMBL17816212 | 0.74 | NPSR1 (0.44) | ALDH1A1GAAL3MBTL1KDM4EMAPT | |
| SCHEMBL17816218 | 0.74 | MAPT (0.43) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL17816208 | 0.73 | POLB (0.41) | L3MBTL1ASPHMAPT | |
| SCHEMBL17808271 | 0.73 | MAPT (0.40) | ALDH1A1GAAARASPHMAPT | |
| SCHEMBL17808248 | 0.72 | ASPH (0.33) | ASPHMAPT | |
| SCHEMBL17808249 | 0.72 | PDE3B (0.35) | ASPHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20160159781-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159781-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | CYP1A2 22/4885CYP3A4 459/4885CYP2C19 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.